Targeted drug tested for Tough-to-Treat thyroid cancer
NCT ID NCT02657551
Summary
This study is testing whether the drug regorafenib can help control metastatic medullary thyroid cancer that has continued to grow despite prior treatments. It is for adults whose cancer has worsened within the last 6 months and who have already tried at least one other targeted therapy. The main goal is to see if the treatment can keep the cancer from progressing for at least 10 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Yale Cancer Center
New Haven, Connecticut, 06520-8028, United States
Conditions
Explore the condition pages connected to this study.